In pancreatic cancer, ZBED2 acts as an antagonist of IRF1 and, along with Recombination Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJ) and ETS Variant Transcription Factor 1 (ETV1), is implicated in an exhausted T-cell phenotype (212). Here, ETV1 is linked to pancreatic neoplasm.